Impact of Casirivimab-Imdevimab on Severe Acute Respiratory Syndrome Coronavirus 2 Delta Variant Nasopharyngeal Virus Load and Spike Quasispecies

BACKGROUND: The increasing use of monoclonal antibodies (mAbs) to treat coronavirus disease 2019 raises questions about their impact on the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mAb-resistant variants. We assessed the impact of Casirivimab-Imdevimab on SARS-CoV-2...

Descripción completa

Detalles Bibliográficos
Autores principales: Vellas, Camille, Del Bello, Arnaud, Gaube, Geraldine, Tremeaux, Pauline, Jeanne, Nicolas, Ranger, Noemie, Martin-Blondel, Guillaume, Delobel, Pierre, Kamar, Nassim, Izopet, Jacques
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8903465/
https://www.ncbi.nlm.nih.gov/pubmed/35299988
http://dx.doi.org/10.1093/ofid/ofac093

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8903465/
https://www.ncbi.nlm.nih.gov/pubmed/35299988
http://dx.doi.org/10.1093/ofid/ofac093

Ejemplares similares